为了应对 COVID-19 大流行，大流行乳腺癌联盟 (PBCC) 发布了乳腺癌患者分诊建议。这些建议包括对手术延迟的早期乳腺癌患者进行新辅助治疗。本研究根据分诊指南评估了全国新辅助治疗模式。从国家癌症数据库收集了 2018-2020 年接受手术（前期或新辅助治疗后）的患者。计算了 2020 年根据 PBCC 分诊指南接受治疗的患者比例，并与 2018-2019 年的类似队列进行比较。评估患者和医院因素与治疗的相关性。在 cT1N0 ER /PR /HER2- 患者中，与之前的患者相比，2020 年接受治疗的患者更有可能接受新辅助内分泌治疗 (NET)（优势比 [OR]，3.08） ；范围，2.93-3.24）。在 cT2N0 或 cT1N1 疾病患者中，2020 年 NET 更为常见（OR，1.76；范围，1.65-1.88）。学术设施、黑人或亚洲人种、更多合并症以及新英格兰/中大西洋地区与 NET 使用相关。在 COVID-19 大流行期间，观察到手术乳腺癌患者新辅助治疗的使用扩大。与通常的做法相反，大流行期间医疗保健系统的限制导致早期乳腺癌新辅助治疗的广泛采用。应密切监测根据 PBCC 建议治疗的患者的长期结果。© 2024。作者。

In response to the COVID-19 pandemic, the Pandemic Breast Cancer Consortium (PBCC) published recommendations for triage of breast cancer patients. The recommendations included neoadjuvant treatment of early-stage breast cancer patients experiencing delays in surgery. This study evaluated national patterns of neoadjuvant treatment according to triage guidelines.Patients treated with surgery (upfront or post-neoadjuvant) in 2018-2020 were collected from the National Cancer Database. The proportions of patients treated according to the PBCC triage guidelines were calculated in 2020 and compared with similar cohorts in 2018-2019. Patient and hospital factors were evaluated for association with treatment.Among cT1N0 ER+/PR+/HER2- patients, those treated in 2020 were more likely to receive neoadjuvant endocrine therapy (NET) compared with those before that time (odds ratio [OR], 3.08; range, 2.93-3.24). Among the patients with cT2N0 or cT1N1 disease, NET was more common in 2020 (OR, 1.76; range, 1.65-1.88). Academic facility, black or Asian race, more comorbidities, and the New England/Middle Atlantic region were associated with NET use.During the COVID-19 pandemic, expanded utilization of neoadjuvant therapy for surgical breast cancer patients was observed. Health care system limitations during the pandemic contributed to expanded adoption of neoadjuvant therapy for early breast cancer, contrary to usual practice. Long-term outcomes for patients treated according to PBCC recommendations should be closely monitored.© 2024. The Author(s).